A Phase I, Single-center, Open-label, Fixed-sequence Clinical Study to Evaluate the Effects of Multiple Administrations of Rifampin or Itraconazole on the Pharmacokinetic Characteristics of a Single Administration of Orelabrutinib Tablets in Healthy Subjects
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Orelabrutinib (Primary) ; Itraconazole; Rifampicin
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Idiopathic thrombocytopenic purpura; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple sclerosis; Neuromyelitis optica; Systemic lupus erythematosus; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors InnoCare Pharma
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 12 Apr 2022 New trial record